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Soo-Yon Rhee,4 Justen Manasa,5 Tiago Gräf,1 Lara Lewis,2 Cherie Cawood,6 David Khanyile,6
Karidia Diallo,7 Kassahun A. Ayalew,7 Robert W. Shafer,4 Gillian Hunt,8,9 Deenan Pillay,10,11
Salim Karim Abdool,2 and Tulio de Oliveira1,2
Abstract
There is evidence of increasing levels of pretreatment HIV drug resistance (PDR) in Southern Africa. We used
data from two large population-based HIV surveillance studies to estimate prevalence of PDR in KwaZulu-
Natal, the province with the highest HIV prevalence in South Africa. Sanger sequencing was performed on
samples obtained from a longitudinal HIV surveillance program (study A, 2013–2014) and the HIV Incidence
Provincial Surveillance System (study B, 2014–2015). Sequences were included for adult HIV positive par-
ticipants (age ‡15 years for study A, age 15–49 years for study B) with no documented prior exposure to
antiretroviral therapy (ART). Overall and drug class-specific PDR was estimated using the World Health
Organization 2009 surveillance drug resistance mutation (SDRM) list, and phylogenetic analysis was performed
to establish evidence of drug resistance transmission linkage. A total of 1,845 sequences were analyzed (611
study A; 1,234 study B). An overall PDR prevalence of 9.2% [95% confidence interval (CI) 7.0–11.7] was
observed for study A and 11.0% (95% CI 8.9–13.2) for study B. In study B, the prevalence of non-nucleoside
reverse-transcriptase inhibitor (NNRTI) PDR exceeded 10% for sequences collected in 2014 (10.2%, 95% CI
7.5–12.9). The most prevalent SDRMs were K103NS (7.5%), M184VI (2.4%), and V106AM (1.4%). There was
no evidence of large transmission chains of drug-resistant virus. High level NNRTI PDR (>10%) suggests a
need to modify the standard first-line ART regimen and to focus attention on improving the quality of HIV
prevention, treatment, and care.
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Introduction
After approximately two decades of combinationantiretroviral therapy (ART), the global response to HIV
is threatened by the development of HIV drug resistance
(HIVDR).1 Pretreatment HIV drug resistance (PDR) refers to
the presence of drug resistance in a person initiating or re-
initiating ART and can therefore be a combination of trans-
mitted and acquired drug resistance (ADR). Such resistance
is considered the best indicator to guide the selection
of effective first-line ART regimens.2–4 While the levels of
PDR in low- and middle-income countries have been low
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to moderate historically, there are concerns over increas-
ing levels, given the rapid expansion in ART access and the
persistent high incidence of new HIV infections.5 Once
PDR exceeds 10%, modeling suggests that in Africa,
HIVDR could account for almost half a million new in-
fections, and $6.5 billion in additional ART costs between
2016 and 2030.6
As part of its coordinated approach to prevent, monitor,
and respond to the emergence of HIVDR, the World Health
Organization (WHO) recommends surveys of PDR.4 As
more people receive ART and develop ADR, the risk of
transmission of drug-resistant HIV increases.7 The presence
of PDR can lead to inadequate virologic suppression on ART
and further accumulation of drug resistance mutations,8,9 and
as a result, the levels of PDR have to be continually moni-
tored to ensure the effective use of ART. At this critical
juncture in the global response to HIV, with scale-up of
universal test-and-treat and pre-exposure prophylaxis (PrEP)
for HIV prevention,10 it is important to understand the current
epidemiology of PDR in high-prevalence settings.
South Africa has the largest ART program in the world,
with *3.9 million people on treatment as of August 2017.11
Generally, low levels of PDR have been documented in the
country,12,13 but there is recent evidence of higher levels,
which raises concern over the continued effectiveness of first-
line non-nucleoside reverse-transcriptase inhibitor (NNRTI)-
based ART regimens.14–16 The evidence of increasing PDR is
in the context of a growing number of people with virological
failure on ART and delayed switching to second-line ART,
creating an expanding pool of those with ADR.17 In this ar-
ticle, we present estimates of PDR from two population-




The Africa Health Research Institute (AHRI) has con-
ducted longitudinal population-based HIV surveillance in the
uMkhanyakude District Municipality, northern KZN since
2003 (Study A, Fig. 1).18 All individuals 15 years and older
in a population of *65,000 resident members are invited
to provide dried blood spot (DBS) specimens on an annual
basis. For this study, viral reverse transcription polymerase
chain reaction (PCR) was performed on the DBS specimens
of the participants with a positive HIV enzyme-linked im-
munosorbent assay (ELISA) in 2013 or 2014, who had a DBS
HIV RNA ‡10,000 copies/mL. PCR and sequencing were
also attempted on some DBS specimens with HIV RNA
<10,000 copies/mL, but this was not pursued as the rate of
successful amplification was low. We excluded sequences
obtained from participants with documented ART initiation
before the date of specimen collection. Information about
ART use was obtained through linkage of the population
surveillance data with routine HIV program data.19 This did
not include information about prior use of antiretrovirals for
prevention of mother-to-child transmission (pMTCT). We
estimated the date of HIV infection using the midpoint be-
tween the last negative test date and the first positive test date
and estimated the duration of infection in months, by calcu-
lating the time between the estimated date of infection and
the sample collection date, as described previously.14
Epicentre AIDS Risk Management, The Centre for the
AIDS Programme of Research in South Africa (CAPRISA),
and the United States Centers for Disease Control and Pre-
vention (CDC) coordinate the HIV Incidence Provincial
Surveillance System (HIPSS) in two subdistricts of uMgun-
gundlovu District Municipality in central KZN (Study B,
Fig. 1).20–22 In 2014–2015, a representative cross-sectional
household survey enrolled 9,812 individuals aged 15–49
years. A multistage cluster sampling technique was used to
randomly select the households and individuals included in
the study, as described previously.23 One individual was se-
lected per household. From the 14,618 households found and
occupied, 9,812 individuals were eligible and consented to
participate. HIV ELISA was performed on the peripheral
blood specimens of the participants,22 and sequencing was
performed on the plasma specimens from participants
with positive HIV serology and plasma HIV RNA ‡1,000
copies/mL.21 For the analysis, we excluded sequences from
those who self-reported any prior ART use (for treatment or
pMTCT). Details on the timing of recruitment and ascertain-
ment of ART status for the two population-based studies are
provided in Supplementary Data.
Laboratory methods and data analysis
Genotypic drug resistance testing of the HIV-1 reverse
transcriptase (RT) and protease (PR) genes was done on
stored specimens by Sanger sequencing on an ABI 3130
Genetic Analyzer (Applied Biosystems, Foster City, CA)
using previously described methods.24 Sequence quality and
coverage were assessed using the Calibrated Population
Resistance (CPR) tool (http://cpr.stanford.edu/cpr.cgi). Se-
quences that had quality concerns, such as stop codons, or
that did not cover all possible surveillance drug resistance
mutation (SDRM) positions, were excluded. We included
participants with complete RT sequences, with or without the
PR sequence.
PDR was determined by detecting SDRMs with the CPR
tool using the WHO 2009 SDRM list.25,26 The results were
used to estimate the levels of overall and drug class-specific
resistance for each study, with the data being analyzed
using STATA version 15.1 (StataCorp, College Station,
TX) and SAS version 9.4 (SAS Institute, Cary, NC). The
chi-square test was used to establish any difference in PDR
prevalence across the years, within each study, with a Rao-
Scott chi-square test being used for study B to adjust for the
survey design. Logistic regression analysis was performed
to explore associations between PDR and individual par-
ticipant characteristics for each study (i.e., sex, age, HIV
RNA, and for study A; the estimated duration of infection)
and accounted for the survey sample design in study B.
Where appropriate, analyses for study B were conducted by
applying sampling weights and using survey procedures.
The sampling weights were adjusted for nonequal proba-
bilities of selection associated with the complex survey
design and for nonresponse across age and gender cate-
gories.20 The confidence intervals (CIs) were calculated
using Wald confidence limits, and the Taylor series line-
arization method was used to estimate standard errors of
proportions.
To establish evidence of SDRM transmission, we per-
formed phylogenetic analysis to identify HIV transmission
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clusters. Sequences with drug resistance mutations identified
in this study were aligned with a background dataset of
15,313 HIV-1 subtype C pol sequences. This consisted of
publicly available sequences from the Los Alamos HIV
Database (www.hiv.lanl.gov), isolated from Southern Afri-
can countries, and sequences generated previously from the
AHRI surveillance population.14,17,27 To avoid cluster for-
mation due to convergent evolution under ART pressure,
codon positions associated with drug resistance mutations
were removed from the alignment.28
A maximum likelihood (ML) phylogenetic tree was
constructed using FastTree2,29 and cluster support was
assessed with Shimodaira–Hasegawa approximate likeli-
hood ratio test (SH-aLRT) with 1,000 pseudo-replicates.
HIV-1 transmission clusters were identified from the ML
tree using the ClusterPicker software version 1.2.3,30 where
the definitions of a transmission cluster were set to a min-
imum clade support of 90 SH-aLRT and a maximum
within-cluster genetic distance of 4.5%. To identify if se-
quences clustering together had similar SDRMs, we further
submitted the full-length sequences (with all codon posi-
tions) to the CPR tool.
Ethics statement
Approval for the two studies was obtained from the Bio-
medical Research Ethics Committee of the University of
KwaZulu-Natal (UKZN) (reference nos. BF233/09 and
BF269/13), the KZN Provincial Department of Health
(HRKM 08/14), and the Center for Global Health, CDC.
Written informed consent for use of stored specimens was
obtained from all study participants.
Results
A total of 1,845 HIV-1 sequences were included in the
analysis and consisted of 611 sequences for study A, with 254
from 2013 and 357 from 2014. From study B, 1,234 se-
quences were included, with 737 from 2014 and 497 from
2015 (Fig. 2).
Overall, 1,841 had complete RT and PR sequences, and 4
had only the complete RT sequence. The characteristics of the
participants included in the analysis are summarized in
Table 1. The estimated prevalence of PDR was 9.2% (95% CI
7.0–11.7) for study A and 11.0% (95% CI 8.9–13.2) for study
B. The estimated prevalence of NNRTI PDR was 7.5% (95%
CI 5.6–9.9) for study A and 9.2% (95% CI 7.2–11.3) for study
B. There was no evidence of an increase in overall PDR or
NNRTI PDR across the 2 years in either study (Fig. 3). The
estimated prevalence of PDR was higher for women than
men in both studies: 9.9% versus 7.1% for study A [odds
ratio (OR) 1.45, 95% CI 0.73–2.87] and 13.6% versus 8.3%
for study B (OR 1.73, 95% CI 1.06–2.81) (Table 2 and
Supplementary Fig. S1).
The prevalence of PDR peaked at 17.0% (95% CI 11.9–
22.1) in women aged 25–34 years in study B (Supplementary
Table S1). There was no strong evidence of an association
between PDR and age or HIV RNA in either study (Table 2).
In study A, the prevalence of PDR was lower in those with an
estimated duration of infection £24 months than in those with
estimated duration >24 months (3.0% vs. 8.6%), but the
analysis was limited by small numbers with recent infection
(n = 66) (Table 2).
Of all 1,845 sequences across the two studies, 212 (11.5%)
had at least one SDRM. The frequency of individual SDRMs
by study year is displayed in Table 3. Overall, 182/1,845
FIG. 1. Location of the two population-based studies.
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(10.0%) had NNRTI mutations, 59/1,845 (3.2%) had nucle-
oside reverse-transcriptase inhibitor (NRTI) mutations, and
23/1,841 (1.2%) had protease inhibitor (PI) mutations
(Table 3). Of those with SDRMs, 162 (76.4%) had single
class resistance, 48 (22.6%) dual class resistance, and 2
(1.0%) triple class resistance. The most frequently observed
SDRM was the NNRTI mutation K103NS, occurring in 139
participants (7.5% of all participants or 65.6% of those with
SDRMs). In 100 participants (47.2% of those with drug re-
sistance mutations), the K103NS mutation was the only
SDRM detected. The most frequently observed patterns of
SDRMs are listed in Supplementary Table S2.
The most common NRTI mutation was M184VI (2.4%), and
in almost all cases (43 of 44) it was detected in combination
FIG. 2. Summary of the specimens and HIV-1 sequences from the two studies in KZN, South Africa. aExcluded due to
incomplete RT sequences. KZN, KwaZulu-Natal Province; RT, reverse transcriptase.
Table 1. Study Participants’ Demographic and Clinical Characteristics
Total
AHRI surveillance (study A) HIPSS (study B)
2013 2014 2014 2015
Participants 1,845 254 357 737 497
Sex, female, n (%) 1,269 (69) 186 (73) 269 (75) 507 (69) 307 (62)
Age, years, median (IQR) 30 (25–39) 30 (24–40) 33 (26–42) 30 (24–38) 30 (24–36)
HIV RNA, log10 copies/mL,
median (IQR)a
4.50 (4.02–4.96) 4.77 (4.35–5.18) 4.70 (4.36–5.10) 4.39 (3.80–4.87) 4.41 (3.91–4.83)
aHIV RNA missing for 84 participants (77 study A, 7 study B).
AHRI, Africa Health Research Institute; HIPSS, HIV Incidence Provincial Surveillance System; IQR, interquartile range.
132 CHIMUKANGARA ET AL.
with at least one NNRTI mutation, and in half the cases (22 of
44) with other NRTI mutations. The K65R mutation associ-
ated with tenofovir (TDF) resistance was detected in 11
participants overall (0.6%), with no evidence of an increase
across the 2 years in either study. Of the 23 with PI mutations,
20 had a single PI mutation. The most common PI mutation
was the M46IL mutation, occurring in 18 participants. Two
participants with four or more PI mutations had similar pat-
terns of PI resistance (M46I, I54V, L76V, V82A), with one
participant having in addition the L90M mutation. In both
cases, there was triple class resistance with NRTI mutations
(M184V, L74V) and an NNRTI mutation (K103S).
From the phylogenetic analysis, we identified 25 trans-
mission clusters with individuals harboring at least one PDR
mutation in common (Supplementary Fig. S2). In total, 57
individuals were grouped in these transmission clusters, 56%
(32/57) were from studies A and B, and 44% (25/57) were
South African individuals whose sequences were present in
the background dataset. Individuals from studies A and B
(in the transmission linkages) comprised 15% (32/212) of the
sequences with any PDR mutations identified here. From the
background dataset, we had information about ART exposure
for 18 of the 25 individuals. Sixteen of the 18 (89%) were
ART experienced and were linked to 14 ART-naive indi-
viduals with PDR (Supplementary Fig. S2). K103NS was the
most common PDR mutation, observed in 72% (41/57) of
individuals involved in linked transmissions.
Discussion
Surveillance of HIVDR is a key component of the public
health approach to sustainable use of ART. In this analysis,
we found moderate-to-high levels of PDR in two KZN
districts between 2013 and 2015, at approximately the turn
FIG. 3. Levels of pretreat-
ment drug resistance (A)
and NNRTI-specific pre-
treatment drug resistance
(B). Marker line in (B) cor-
responds to 10% threshold
for NNRTI PDR. Prevalence
estimates and confidence in-
tervals for study B were
weighted to adjust for the
survey design and for non-




pretreatment HIV drug re-
sistance.
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of the second decade of ART rollout. The results from the
AHRI longitudinal population surveillance suggest a con-
tinued trend of steadily increasing PDR since 2010.14 In the
HIPSS cross-sectional survey, the level of NNRTI PDR was
close to 10%, the current threshold at which the WHO rec-
ommends urgent public health action.2,3 The attempt to ex-
clude people with prior ART exposure means that our findings
are likely to reflect predominantly transmitted resistance. The
levels of resistance documented and the phylogenetic analysis
therefore suggest increasing transmission of HIVDR from
people treated with ART. This raises concerns about the
quality of HIV prevention, treatment, and care and should
prompt consideration of appropriate public health measures to
ensure the long-term sustainability of ART.
The timing of this increase in levels of PDR is consistent
with other findings from sub-Saharan Africa, where PDR rose
to moderate levels about 10 years into ART scale-up.31,32 To
some extent, our findings are consistent with a nationally
representative survey conducted in South Africa in 2013–
2014, which estimated the prevalence of PDR at 9.0% and
NNRTI PDR at 8.3% nationally.15 The two sites are similar in
terms of demographics, HIV epidemiology, and HIV care
cascades.22,33 However, there were some differences in the
study populations, particularly the higher HIV RNA levels in
study A due to the use of DBS samples for sequencing, as the
amplification success rate reduces at lower HIV RNA levels
(<10,000 copies/mL) in DBS samples.34 Using DBS samples,
which have a higher HIV RNA requirement for genotyping,
could have resulted in an underestimation of the levels of
resistance for study A, as drug-resistant viruses have a lower
replicative capacity than the wild-type virus, which could
result in lower HIV RNA levels, although this may depend on
the specific profile of mutations.35,36
Another difference between the two studies was the
method used to determine prior ART use. It is possible that
the self-report of ART use in the HIPSS (study B) was less
reliable than linkage to health service records as a method for
uncovering current or prior use of ART. Significant undis-
closed ART use has been documented in other population-
based surveys,37,38 and if people on ART were inadvertently
included in the sample for this analysis, then the levels of
PDR from the HIPSS (study B) may be overestimated. Given
these difficulties, it is possible that future studies should in-
clude testing for antiretroviral drug levels to determine the
true ART status. Although the PDR prevalence was some-
what higher in women in both studies, the difference was not
as marked as that reported for a number of recent national
PDR surveys.5 In addition, we did not observe a clear gra-
dient in PDR across age groups, unlike a recent study in
Kenya,39 although it is notable that PDR levels were partic-
ularly high in young women, the group with the highest HIV
incidence in these populations.21
The rapid expansion of ART coverage has been a con-
siderable achievement in South Africa, having resulted in
substantial gains in life expectancy.40,41 Routine viral load
(VL) monitoring to guide ART switches has been incorpo-
rated into the treatment program since the start of ART
rollout. Despite this, implementation remains inconsistent,
and the results are often not appropriately acted upon.42–45
With the resulting delays in switching to second-line ART
regimens, people spend more time being viremic and at risk
of accumulating drug resistance.17 With the growing case-
loads of people on first-line ART, this suggests that there will
be an expanding pool of people with ADR, creating condi-
tions for an increase in the transmission of HIVDR.46 Our
findings lend support to calls for increased focus on quality
Table 2. Association Between Pretreatment Drug Resistance and Participant Characteristics
Category
Study A Study B
N n (%) OR (95% CI) N n (%) OR (95% CI)
Sex
Male 156 11 (7.1) 1 420 39 (9.3) 1
Female 455 45 (9.9) 1.45 (0.73–2.87) 814 117 (14.4) 1.64 (1.12–2.41)
Age, years
15–24 145 15 (10.3) 1.28 (0.62–2.62) 314 40 (12.7) 0.88 (0.58–1.34)
25–34 217 18 (8.3) 1 507 72 (14.2) 1
35–44 125 10 (8.0) 0.96 (0.43–2.15) 319 30 (9.4) 0.63 (0.40–0.98)
45+ 124 13 (10.5) 1.29 (0.61–2.74) 94 14 (14.9) 1.06 (0.57–1.97)
HIV RNA, log10 copies/mL
<4 51 4 (7.8) 1 372 61 (16.4) 1
4–5 309 33 (10.7) 1.40 (0.48–4.15) 619 61 (9.9) 0.56 (0.38–0.82)
>5 174 14 (8.0) 1.03 (0.32–3.27) 236 33 (14.0) 0.83 (0.52–1.31)
Missing 77 5 (6.5) 0.82 (0.21–3.20) 7 1 (14.3) 0.85 (0.10–7.18)
Duration of infectiona
£24 months 66 2 (3.0) 0.33 (0.08–1.42) — — —
>24 months 385 33 (8.6) 1 — — —
Unknown 160 21 (13.1) 1.61 (0.90–2.88) — — —
aFor those with a prior negative HIV ELISA in the population surveillance, estimated date of infection was calculated as midpoint
between last negative HIV ELISA and first positive HIV ELISA. Estimated duration of infection was then calculated from that date of
infection to the date that the sample processed for sequencing was collected. For those with only prior positive HIV ELISA tests, duration
of infection was taken to be >24 months if there was a positive HIV ELISA more than 24 months before the sample date. Unknown duration
of infection implies no prior negative HIV ELISA and no prior positive HIV ELISA beyond 24 months.
CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; OR, odds ratio.
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improvement within the HIV treatment program, particularly
with respect to adherence support, routine virologic moni-
toring, and timely ART switching.44,45
Overall, around 1 in 10 participants had at least one
NNRTI SDRM, the most frequent mutation being K103NS,
which is consistent with the national PDR survey,15 and is the
most common NNRTI mutation documented in the context of
ADR on first-line ART.47 The persistence of this mutation in
the absence of drug pressure48 may increase the chance of
onward transmission, and the levels documented here raise
concern about the continued effectiveness of efavirenz (EFV)
and nevirapine in first-line regimens. The levels of NRTI
resistance were relatively low, and the estimated prevalence
of key SDRMs associated with TDF resistance (K65R and
K70E) was below 1% in both studies. This was also consis-
tent with the national survey that estimated the prevalence of
K65R at 1.4%.15 At the time of these studies, TDF had still
only been in widespread use in first-line ART regimens for
under 5 years, so continued vigilance is required, especially
as high levels of K65R have been documented in those with
ADR on first-line ART, and with evidence supporting the
transmissibility of K65R variants.47,49 However, these find-
ings provide reassurance for now about the place of TDF in
first-line ART and PrEP regimens.50 Although the levels of
Table 3. Surveillance Drug Resistance Mutations Detected in Two Population-Based Studies
in KwaZulu-Natal Province, South Africa
AHRI surveillance (study A) HIPSS (study B)
Overall2013 2014 2014 2015
NNRTI mutations n = 254 n = 357 n = 737 n = 497 n = 1,845
L100I 0 0 0.4 0.2 0.2
K101EP 0.8 0.3 1.1 0.6 0.8
K103NS 6.3 6.2 9.2 6.6 7.5
V106AM 0.8 0.8 2.0 1.0 1.4
Y181C 0.4 0 0.1 0.6 0.3
Y188LC 0.4 0 0.3 0.6 0.3
G190AS 0 0.8 0.7 0.2 0.5
P225H 1.2 0.8 1.1 0.8 1.0
M230L 0 0.3 0.4 0.2 0.3
Overall NNRTI resistance 7.5 7.6 11.9 9.7 9.9
NRTI mutations n = 254 n = 357 n = 737 n = 497 n = 1,845
M41L 0 0.3 0.3 0.2 0.2
K65R 1.2 0.3 0.7 0.4 0.6
D67N 0.8 0 0.1 0.4 0.3
T69D 0 0.3 0 0 0.1
K70R 0.8 0 0 0.4 0.2
K70E 0.0 0.3 0.0 0.6 0.2
L74VI 0.4 0.3 0.1 0.2 0.2
Y115F 0 0 0.3 0.2 0.2
M184VI 3.1 2.0 2.6 2.0 2.4
L210W 0 0 0.1 0 0.1
T215DEV 0.4 0 0.1 0 0.1
T215Y 0.4 0 0 0 0.1
K219ENR 0.8 0.6 0.3 0.2 0.4
Overall NRTI resistance 4.7 3.4 3.1 2.4 3.2
PI mutationsa n = 254 n = 356 n = 736 n = 495 n = 1,841
L24I 0 0 0 0.2 0.1
M46IL 0.4 0.6 0.7 2.0 1.0
F53Y 0 0 0 0.2 0.1
I54V 0.4 0.3 0 0 0.1
L76V 0.4 0.3 0 0 0.1
V82A 0.4 0.3 0 0 0.1
I85V 0 0.3 0 0.4 0.2
L90M 0.8 0 0 0 0.1
Overall PI resistance 0.8 0.8 0.7 2.6 1.2
All figures are percentages; figures in bold are levels of resistance ‡5%. The following surveillance drug resistance mutations were not
detected in either study and are therefore not listed: L23I, D30N, V32I, I47VA, G48VM, I50LV, G73STCA, N83D, I84VAC, N88DS,
T69ins, V75MTAS, F77L, F116Y, Q151M, and V179F.
aDenominator for PI mutations based on number of complete PR sequences.
NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
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PI resistance were low, the two instances of multiple major PI
mutations and triple class resistance raise some concern. The
information available from the public sector health records
suggested that neither had been exposed to ART. However,
multiple major PI mutations and triple class resistance sug-
gest that the two individuals had prior use of ART. Therefore,
these findings should be interpreted with caution, given the
potential for data linkage problems, access to ART in a public
sector program outside the study area, or access to ART in the
private sector.
From the phylogenetic analysis, *15% of the individuals
with SDRM from study A and B were linked in a transmission
cluster with at least one other person with an identical SDRM.
Fourteen of 32 ART-naive individuals were linked with
ART-experienced individuals whose sequences were in the
background dataset. In these linkages, we can infer that drug-
resistance mutations were most likely transmitted from ART-
experienced individuals to ART-naive individuals in the
same cluster. For the other 18 ART-naive individuals with
PDR, the source of drug resistance is most likely to be from
ART-experienced individuals that were not part of our study
sample, although we cannot exclude onward transmission
from ART-naive individuals and undisclosed ART exposure.
K103N was the most common mutation observed in the
linked cases, consistent with a study from Aruba, a highly
HIV endemic area in the Caribbean.51 However, unlike the
Aruba cluster, where onward transmission of K103N was
observed among ART-naive individuals in a large transmis-
sion chain, the pattern of small and independent transmission
clusters observed here is more suggestive of multiple trans-
mission events from people with ADR on ART.
Our findings suggest that additional public health inter-
ventions may now be required in South Africa, as recommended
by the WHO.2,3 One option would be to introduce genotypic
resistance testing before ART initiation, but this would have
substantial cost implications and present considerable oper-
ational challenges. The more likely option would be to
change the standard first-line ART regimen, probably to an
integrase inhibitor-based regimen. Dolutegravir (DTG) has al-
ready replaced EFV in first-line ART in neighboring Botswana,
and there are plans for it to be introduced for first-line ART in
South Africa in 2019.11,52 While there are some concerns about
introducing DTG in the South African context (e.g., with pau-
city of studies on the use of DTG in pregnancy and dosing in
people with tuberculosis on rifampicin), cost savings are an
additional driver to adopt this for first-line therapy.52
Our findings should be interpreted with certain limitations,
as the two studies were not conducted as formal drug resistance
surveys for pretreatment or transmitted drug resistance. Al-
though population-based studies present challenges in accu-
rately determining current and prior ART use, they might have
some advantages over facility-based HIVDR surveys in that
they include a more broadly representative sample of HIV-
positive people in the population, including people not acces-
sing health care. However, this representativeness is dimin-
ished if there are low levels of consent in population-based
surveys, as seen in the AHRI surveillance.53 There was sub-
stantial attrition in the laboratory processes, particularly with
the DBS specimens, and we cannot be certain that the partici-
pants whose virus was successfully sequenced were represen-
tative of all eligible ART-naive people in the study populations.
Our capacity to uncover linked drug resistant transmissions was
limited by the relatively low coverage of people living with
HIV in the study areas, particularly for study B. Finally, as these
studies were in geographically restricted populations, these
results should not be taken to be representative of the entire
province of KZN, or of South Africa more generally.
In conclusion, the high levels of PDR documented here
highlight the need for renewed focus on improving the
quality of HIV prevention, treatment, and care. In particular,
the systems for routine VL monitoring for people on ART
and switching to second-line ART should be strengthened.
These findings should be interpreted together with results of
the national drug resistance survey to inform the need for
modification of the standard first-line ART regimen or the
introduction of other public health measures to prevent the
spread of drug resistance.
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